|
TTC19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.80710000039642E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73400999999851E-05 |
| Normal-vs-Stage2 |
2.479000E-03 |
| Normal-vs-Stage3 |
2.04390000035914E-07 |
| Normal-vs-Stage4 |
3.09809999998745E-06 |
| Stage1-vs-Stage2 |
5.732400E-01 |
| Stage1-vs-Stage3 |
2.275200E-01 |
| Stage1-vs-Stage4 |
1.983360E-01 |
| Stage2-vs-Stage3 |
1.672350E-01 |
| Stage2-vs-Stage4 |
1.511820E-01 |
| Stage3-vs-Stage4 |
7.056200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.16510000039527E-07 |
| Normal-vs-AfricanAmerican |
4.034300E-02 |
| Normal-vs-Asian |
8.3314999999029E-07 |
| Caucasian-vs-AfricanAmerican |
4.269200E-01 |
| Caucasian-vs-Asian |
4.341600E-01 |
| AfricanAmerican-vs-Asian |
2.991000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.11840000000174E-06 |
| Normal-vs-Female |
2.0712999999617E-06 |
| Male-vs-Female |
7.185600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.74779999999797E-05 |
| Normal-vs-Age(41-60Yrs) |
1.62510000001337E-06 |
| Normal-vs-Age(61-80Yrs) |
2.0122999999983E-05 |
| Normal-vs-Age(81-100Yrs) |
2.960200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.065000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.201000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.176400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.241400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.529200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.426000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.670190E-01 |
| Classical-VS-Follicular |
3.873800E-01 |
| Classical-VS-Other |
1.217960E-01 |
| Classical-VS-Normal |
1.29220000000263E-06 |
| Tall-VS-Follicular |
5.490500E-02 |
| Tall-VS-Other |
3.638200E-01 |
| Tall-VS-Normal |
2.44689999995273E-06 |
| Follicular-VS-Other |
1.619950E-01 |
| Follicular-VS-Normal |
3.179200E-03 |
| Other-VS-Normal |
7.989600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.13930000003693E-06 |
| Normal-vs-N1 |
2.38649999761975E-08 |
| N0-vs-N1 |
9.578300E-03 |
|
|
